Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2009 Mar 15;69(6):2487-96. doi: 10.1158/0008-5472.CAN-08-2611. Epub 2009 Mar 10.

Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Author information

1
Department of Pathology and Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. shurinmr@upmc.edu

Abstract

Dendritic cells (DC) loaded with tumor antigens from apoptotic/necrotic tumor cells are commonly used as vaccines for cancer therapy. However, the use of dead tumor cells may cause both tolerance and immunity, making the effect of vaccination unpredictable. To deliver live tumor "cargoes" into DC, we developed a new approach based on the "labeling" of tumors with a phospholipid "eat-me" signal, phosphatidylserine. Expression of phosphatidylserine on live tumor cells mediated their recognition and endocytosis by DC resulting in the presentation of tumor antigens to antigen-specific T cells. In mice, topical application of phosphatidylserine-containing ointment over melanoma induced tumor-specific CTL, local and systemic antitumor immunity, and inhibited tumor growth. Thus, labeling of tumors with phosphatidylserine is a promising strategy for cancer immunotherapy.

PMID:
19276376
PMCID:
PMC4006359
DOI:
10.1158/0008-5472.CAN-08-2611
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center